Brief: Novonesis H1 Adjusted EBITDA Margin 37.7%
BRIEF-Novonesis H1 Adjusted EBITDA Margin 37.7% Aug 19 (Reuters) - Novonesis outlook FY organic growth 7-8%.
Recent news on Novozymes A/S
See all newsGivaudan jumps on fragrance outperformance; peers follow
Europe Research Roundup: IWG, Londonmetric, Sartorius
Brief: Novonesis To Build Next Generation Enzyme Production Facility In India
Next cycle in ingredient makers sector belongs to biotech, Jefferies says
Europe Research Roundup: DSM-Firmenich, Merck, Orsted